Inhibikase Therapeutics (IKT) reported a net loss of $20.5 million, or $0.10 per basic and diluted share, for the third quarter ended September 30, 2026. The company held $193.3 million in cash, cash equivalents and marketable securities at quarter-end.
The company said its Phase 3 IMPROVE-PAH study of IKT-001 had obtained regulatory approvals in 28 countries, with 79 of 180 planned clinical sites activated as of November 2026.
- Research and development expense was $15.0 million in the quarter, compared with $7.6 million a year earlier.
- Selling, general and administrative expense was $7.2 million, compared with $5.6 million in the prior-year quarter.
- In July, Inhibikase sold 25 million common shares to RA Capital Management through its ATM facility for gross proceeds of $50 million.
- An interim safety readout for Part A of IMPROVE-PAH, involving 50 patients, is planned for the first half of 2027.
- The FDA granted Orphan Drug Designation to IKT-001 in July 2026.
$IKT Hedge Fund Activity
We have seen 55 institutional investors add shares of $IKT stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TRAILS EDGE CAPITAL PARTNERS, LP added 2,873,194 shares (+46.5%) to their portfolio in Q2 2026, for an estimated $5,832,583
- PERCEPTIVE ADVISORS LLC removed 2,315,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $4,699,450
- BLACKROCK, INC. added 1,464,624 shares (+23.2%) to their portfolio in Q2 2026, for an estimated $2,973,186
- ALLY BRIDGE GROUP (NY) LLC removed 1,325,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $2,689,749
- MILLENNIUM MANAGEMENT LLC added 1,100,025 shares (+37.6%) to their portfolio in Q2 2026, for an estimated $2,233,050
- ADAR1 CAPITAL MANAGEMENT, LLC added 780,633 shares (+11.8%) to their portfolio in Q2 2026, for an estimated $1,584,684
- SPHERA FUNDS MANAGEMENT LTD. added 649,309 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,318,097
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
